LA
CRXTW

Linden Advisors’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Linden Advisors’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-131,545
Closed -$99K – 779
2021
Q2 		$99K Hold
131,545
– – ﹤0.01% 769
2021
Q1 		$72K Buy
+131,545
New +$105K ﹤0.01% 694

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Linden Advisors's CRXTW Position: Q3 2021 in Review

Linden Advisors sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2021, closing a stake of 131,545 shares — an estimated $99K sold.

Linden Advisors first reported a position in CRXTW in Q1 2021 and held it in 2 quarters. The position peaked at $99K in Q2 2021. 22 funds tracked by Wall St. Rank hold CRXTW as of Q3 2021.

  • Linden Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2021 after selling out during the quarter.
  • Linden Advisors sold 131,545 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2021, an estimated $99K.
  • Linden Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q1 2021 and held it in 2 quarters.
  • Linden Advisors's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $99K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2021.

Based on Linden Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.